Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial

(2018) Stephen D. Wiviott et al.   AMERICAN HEART JOURNAL

Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes

(2018) Daisuke Matsutani et al.   Cardiovascular Diabetology

Estimating Left Ventricular Filling Pressure by Echocardiography

(2017) Oyvind S. Andersen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome

(2016) Hiroaki Kusaka et al.   Cardiovascular Diabetology

Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?

(2016) Subodh Verma et al.   DIABETES CARE

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

(2016) Piotr Ponikowski et al.   EUROPEAN HEART JOURNAL

Preventable Major Cardiovascular Events Associated With Uncontrolled Glucose, Blood Pressure, and Lipids and Active Smoking in Adults With Diabetes With and Without Cardiovascular Disease: A Contemporary Analysis

(2015) Gabriela Vazquez-Benitez et al.   DIABETES CARE

Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction

(2015) Scott D. Solomon et al.   EUROPEAN HEART JOURNAL

Comparison of the reliability of E/E′ to estimate pulmonary capillary wedge pressure in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction

(2015) Kenichi Matsushita et al.   INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING

Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

(2015) Roberto M. Lang et al.   JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes

(2014) Julio Rosenstock et al.   DIABETES CARE

Longitudinal Development of Left Ventricular Diastolic Function in Patients With Type 2 Diabetes

(2014) Laura Venskutonyte et al.   DIABETES CARE

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

(2013) H.-U. Haring et al.   DIABETES CARE

Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction

(2011) Inder S. Anand et al.   Circulation-Heart Failure

Effects of Treatment on Exercise Tolerance, Cardiac Function, and Mortality in Heart Failure With Preserved Ejection Fraction

(2011) David J. Holland et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Treatment of Heart Failure With Normal Ejection Fraction

(2010) Walter J. Paulus et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Glucose Control by the Kidney: An Emerging Target in Diabetes

(2009) Olivera Marsenic   AMERICAN JOURNAL OF KIDNEY DISEASES

Clinical Effectiveness of Beta-Blockers in Heart Failure

(2009) Adrian F. Hernandez et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction

(2009) Carolyn S.P. Lam et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY